Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation-Reference-Cited by-同舟云学术

Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation

Published:2017-11-03 Issue:11 Volume:3 Page:1208-1220
ISSN:2374-7943
Container-title:ACS Central Science
language:en
Short-container-title:ACS Cent. Sci.

Author:

Pan Peichen,Yu Huidong¹,Liu Qinglan²³,Kong Xiaotian,Chen Hu²,Chen Jiean²,Liu Qi²^ORCID,Li Dan,Kang Yu,Sun Huiyong^ORCID,Zhou Wenfang,Tian Sheng,Cui Sunliang^ORCID,Zhu Feng^ORCID,Li Youyong^ORCID,Huang Yong²^ORCID,Hou Tingjun^ORCID

Affiliation:

1. Rongene Pharma Co., Ltd., Shenzhen, Guandong 518054, China

2. Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, Guangdong 518055, China

3. Innovative Drug R & D Center, Shenzhen Salubris Pharmaceuticals Co., Ltd., Huabao Industrial Zone, Shenzhen 518102, China

Funder

Ministry of Science and Technology of the People's Republic of China

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.acs.org/doi/pdf/10.1021/acscentsci.7b00419

Reference48 articles.

1. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer